Delpharm

Delpharm is a leading Contract Development and Manufacturing Organization (CDMO) with 19 plants across France, Italy, Canada, Poland, and The Netherlands, generating over 1.1 billion euros in turnover. The company, established in 1988, boasts a workforce of 6,500 employees and has positioned itself as a key player in the pharmaceutical industry through strategic acquisitions of manufacturing plants, particularly from major pharmaceutical companies. As a multi-specialist, Delpharm is capable of supplying a wide array of pharmaceutical forms, encompassing tablets, capsules, bottles, injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments, and soft gel capsules. Furthermore, the company offers comprehensive development services for various pharmaceutical forms, chemical entities, and innovative combinations, covering the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid, and injectable forms. With a strong foothold in the Health Care, Manufacturing, and Pharmaceutical industries, Delpharm continues to excel in its niche. Although specific details regarding the most recent investment and investors are currently unavailable, the company's widespread operations and significant capabilities make it a noteworthy prospect for potential venture capital opportunities. Delpharm's headquarter is located in France, solidifying its global presence in the pharmaceutical manufacturing landscape.